On May 24, 2010 the FDA approved Genzyme’s LumizymeA form of enzyme replacement therapy used to treat Pompe disease by providing a lab-made version of ... More for the treatment of patients with Pompe diseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup tha... More who are over 8 years of age and do not have evidence of cardiac hypertrophy.
For more information on the approval and how to access treatment, please read the Pompe Program Update.